WebJun 22, 2024 · In other AbbVie news, the company has terminated a four-year-old collaboration deal with Waltham, Mas.-based Morphic Therapeutic. In 2024, AbbVie and Morphic Therapeutic forged a research and development collaboration to advance Morphic’s oral integrin therapeutics, which are designed to block TGF-β activation in … WebAug 25, 2024 · North Chicago, Ill.-based AbbVie Inc. exercised its license option to develop Morphic Holding Inc.'s investigational drugs for fibrotic diseases. Under the agreement, …
AbbVie Exercises Option to License Morphic’s Program for IPF and …
WebMorphic is also eligible for additional, undisclosed clinical and commercial milestone payments and tiered royalties on worldwide net sales for each compound. Morphic … WebApr 8, 2024 · Companies. Morphic Holding Inc. (NASDAQ:MORF) price on Thursday, April 06, fall -1.32% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $34.33. A look at the stock’s price movement, the close in the last trading session was $34.79, moving within a range at $33.94 and $35.335. alec catalano
AbbVie pulls the trigger on Morphic fibrosis programs, adding …
WebAug 25, 2024 · Morphic Therapeutic and AbbVie announced that AbbVie has exercised a license option under the companies’ research and development collaboration agreement … WebJul 1, 2016 · Waltham, Massachusetts-based Morphic Therapeutic announced today that is has completed a Series A financing round worth $51.5 million. It was co-led by SR One and Pfizer Venture Investments, and joined by Omega Funds and AbbVie Ventures. Founding investors were Polaris Partners, TA Springer, Schrodinger Inc., and ShangPharma … WebApr 10, 2024 · Ocular Therapeutix announced a license agreement and a collaboration with AffaMed Therapeutics for the development and commercialization of Dextenza and OTX-TIC in Greater China, South Korea, and the ASEAN markets. alec cannon